NT113, A pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification

Molecular Cancer Therapeutics

Volumn 13, Issue 12, 2014, Pages 2919-2929

  Yoshida, Yasuyuki ^a,e   Ozawa, Tomoko ^a   Yao, Tsun Wen ^a   Shen, Wang ^b   Brown, Dennis ^b   Parsa, Andrew T ^c   Raizer, Jeffrey J ^c   Cheng, Shi Yuan ^c   Stegh, Alexander H ^c   Mazar, Andrew P ^c   Giles, Francis J ^c   Sarkaria, Jann N ^d   Butowski, Nicholas ^a   Nicolaides, Theodore ^a   James, C David ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NewGen Therapeutics Inc   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Mayo Clinic College of Medicine   (United States)

^e ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; LAPATINIB; NT 113; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; NT113 COMPOUND; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BRAIN LEVEL; DRUG RESPONSE; FEMALE; GENE AMPLIFICATION; GLIOBLASTOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTRACRANIAL TUMOR; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; WILD TYPE; XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION; GENETICS; MORTALITY; PATHOLOGY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ERLOTINIB HYDROCHLORIDE; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GLIOBLASTOMA; HUMANS; MICE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84917734689     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0306     Document Type: Article

References (31)

1. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013;310:1842-50.
2. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991;51:2164-72.
3. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000;60:1383-7.
4. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
5. Broniscer A, Panetta JC, O'Shaughnessy M, Fraga C, Bai F, Krasin MJ, et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res 2007;13:1511-5.
6. Wang S, Zhou Q, Gallo JM. Demonstration of the equivalent pharmacokinetic/ pharmacodynamic dosing strategy in a multiple-dose study of gefitinib. Mol Cancer Ther 2009;8:1438-47.
7. Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W, et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastomamultiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 2010;65:353-61.
8. Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2012;2:458-71.
9. Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, et al. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov 2013;3:534-47.
10. Jun HJ, Acquaviva J, Chi D, Lessard J, Zhu H, Woolfenden S, et al. Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. Oncogene 2012;31:3039-50.
11. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 2010;12:95-103.
12. Karpel-Massler G, Westhoff MA, Kast RE, Wirtz CR, Halatsch ME. Erlotinib in glioblastoma: lost in translation? Anticancer Agents Med Chem 2011;11:748-55.
13. Joshi AD, Loilome W, Siu IM, Tyler B, Gallia GL, Riggins GJ. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy. PLoS ONE 2012;7:e44372.
14. Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol 2014;16:567-78.
15. Longo SL, Padalino DJ, McGillis S, Petersen K, Schirok H, Politz O, et al. Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models. Invest New Drugs 2012;30:2161-72.
16. Eisenstat DD, Nabors LB, Mason WP, Perry JR, Shapiro WR, Kavan P, et al. A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma. J Clin Oncol 29: 2011 (suppl; abstr 2010).
17. Yoshida Y, Ozawa T, Butowski N, Shen W, Brown D, Pedersen H, et al. Preclinical evaluation of NT113, a novel ERBB inhibitor optimized for CNS biodistribution. Neurol-Oncology 15: 2013 (suppl; abstr ET-100).
18. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 1994;91:7727-31.
19. Pandita A, Aldape KD, Zadeh G, Guha A, James CD. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 2004;39:29-36.
20. Sarkaria JN, Carlson BL, Schroeder MA, Grogan P, Brown PD, Giannini C, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 2006;12:2264-71.
21. Dinca EB, Sarkaria JN, Schroeder MA, Carlson BL, Voicu R, Gupta N, et al. Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J Neurosurg 2007;107:610-6.
22. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 2005;7:164-76.
23. Ozawa T, James CD. Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. J Vis Exp 2010;13:pii,1986.
24. da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol 2011;6:49-69.
25. Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, et al. Identifi cation of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 2007;6:1167-74.
26. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24.
27. Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 2004;63:700-7.
28. Nelson JM, Fry DW. Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J Biol Chem 2001;276:14842-7.
29. Kohli L, Kaza N, Lavalley NJ, Turner KL, Byer S, Carroll SL, et al. The pan erbB inhibitor PD168393 enhances lysosomal dysfunctioninduced apoptotic death in malignant peripheral nerve sheath tumor cells. Neuro Oncol 2012;14:266-77.
30. Greenall SA, Donoghue JF, Gottardo NG, Johns TG, Adams TE. Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo. Oncogene 2014 Apr 21. [Epub ahead of print]
31. Gorlick R, Kolb EA, Houghton PJ, Morton CL, Phelps D, Schaiquevich P, et al. Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2009;53:594-8.